Loading provider…
Loading provider…
Psychiatry Physician in Sacramento, CA
NPI: 1164658712Primary Practice Location
UNIVERSITY OF CALIFORNIA DAVIS MEDICAL CENTER
4301 X St, Sacramento, CA
Primary Employer
Regents Ucdpbg Psychiatry
health.ucdavis.edu
HQ Phone
Get Kathleen's Phone Numberphone_androidMobile
Get Kathleen's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2010 - 2026
VA State Medical License
2010 - 2020

American Board of Psychiatry and Neurology
Psychiatry
Penn State College of Medicine
med.psu.edu
Medical School
Until 2009
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 23 | 31 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 23 | 63 |
| 3 | 99211Established patient office or other outpatient visit, typically 5 minutes | 17 | 41 |
| 4 | 99443Physician telephone patient service, 21-30 minutes of medical discussion | 15 | 25 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 12 | 16 |
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
Authors: Jean Bennett, Jennifer Wellman, Kathleen A. Marshall, Sarah McCague, Manzar Ashtari, Julie DiStefano-Pappas, Okan U. Elci, Daniel C. Chung, Junwei Sun, J. Fraser Wright, Dominique Cross, Puya Aravand, Laura Cyckowski, Jeannette L. Bennicelli, Federico Mingozzi, Alberto Auricchio, Eric A. Pierce, Jason Ruggiero, Bart P. Leroy, Francesca Simonelli, Katherine A. High, Albert M. Maguire
Publication Date: 2016-08
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
Authors: Vinit Mahajan
Publication Date: 2017-08
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
Authors: Albert M. Maguire, Katherine A. High, Alberto Auricchio, J. Fraser Wright, Eric A. Pierce, Francesco Testa, Federico Mingozzi, Jeannette L. Bennicelli, Gui-Shuang Ying, Settimio Rossi, Ann Fulton, Kathleen A. Marshall, Sandro Banfi, Daniel C. Chung, Jessica I. W. Morgan, Bernd Hauck, Olga Zelenaia, Xiaosong Zhu, Leslie Raffini, Frauke Coppieters, Elfride De Baere, Kenneth S. Shindler, Nicholas J. Volpe, Enrico Maria Surace, Carmela Acerra, Arkady Lyubarsky, T. Michael Redmond, Edwin M. Stone, Junwei Sun, Jenni Fer Uvellman Mcdonnell, Bart P. Leroy, Francesca Simonelli, Jean Bennett
Publication Date: 2009-11